KEEFE LOBB: Open Payments
NPI 1972890523 · MIDLOTHIAN, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,552 in 91 payments from 26 companies in 2025. Trend: 2023 $1,283 · 2024 $1,068 · 2025 $1,552
Food & beverage: $1,552
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $252 |
| PFIZER INC. | 13 | $204 |
| Novo Nordisk Inc | 10 | $159 |
| Lilly USA, LLC | 9 | $150 |
| AstraZeneca Pharmaceuticals LP | 5 | $139 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $86 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $55 |
| Teva Pharmaceuticals USA, Inc. | 3 | $49 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $45 |
| Abbott Laboratories | 2 | $40 |
Products named: QULIPTA, MOUNJARO, NURTEC ODT, FARXIGA, UBRELVY, XIFAXAN, JARDIANCE, Ozempic.
Industry payments across VA — which companies pay providers there.
